A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Public ClinicalTrials.gov record NCT02387957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
Study identification
- NCT ID
- NCT02387957
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2016 (Actual)
- Primary completion
- Jan 2017 (Actual)
- Completion
- Jan 2017 (Actual)
- Last update posted
- Oct 30, 2024
2016 – 2017
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85014 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Sacramento | California | 95819 | — |
| Not listed | Santa Ana | California | 92705 | — |
| Not listed | New London | Connecticut | 06320 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Fort Myers | Florida | 33912 | — |
| Not listed | Augusta | Georgia | 30909 | — |
| Not listed | Oak Forest | Illinois | 60452 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Worcester | Massachusetts | 01605 | — |
| Not listed | Southfield | Michigan | 48034 | — |
| Not listed | Minneapolis | Minnesota | 55435 | — |
| Not listed | Reno | Nevada | 89502 | — |
| Not listed | Rochester | New York | 14620 | — |
| Not listed | Cleveland | Ohio | 44130 | — |
| Not listed | Huntingdon Valley | Pennsylvania | 19006 | — |
| Not listed | Ladson | South Carolina | 29456 | — |
| Not listed | Abilene | Texas | 85014 | — |
| Not listed | Amarillo | Texas | 79106 | — |
| Not listed | San Antonio | Texas | 78240 | — |
| Not listed | The Woodlands | Texas | 77384 | — |
| Not listed | Silverdale | Washington | 98383 | — |
| Not listed | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02387957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2024 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02387957 live on ClinicalTrials.gov.